Literature DB >> 22134018

Uterine leiomyomas, current concepts: pathogenesis, impact on reproductive health, and medical, procedural, and surgical management.

Malcolm G Munro1.   

Abstract

Leiomyomas are such common tumors of the uterus that at least two-thirds of women will have at least one by the age of 50. Despite this high incidence, we know relatively little about their cause, growth and development, and contribution to the genesis of reproductive disorders. The prevalence of lesions puts women with associated butun related symptoms at risk for unnecessary and/or unsuccessful interventions,especially if they have not been carefully evaluated and counseled. Indeed, because the majority of leiomyomas do not cause symptoms, when a woman presents with AUB, infertility, pelvic pain, or vague abdominal complaints, it is possible if not likely that the cause of the problem exists elsewhere. The other overwhelming impression that can be gleaned is this: when leiomyomas are the cause of the symptoms,particularly in women desiring to preserve fertility, the tumors have already and frequently induced irreparable harm, a circumstance that cries out for a strategy of early detection and interventions designed to minimize morbidity.Fortunately, because of the efforts of a few, we are just beginning to understand the potential molecular mechanisms by which leiomyomas may contribute to reproductive tract symptoms such as AUB, infertility, and pregnancy loss, work that may contribute to the development of more specific medical therapeutic techniques and strategies. The use of increasingly precise and accessible imaging for diagnosis,combined with the application of customized intrauterine drug-releasing systems or minimally invasive and highly accurate targeted ablative technologies that minimize collateral damage, may provide women the opportunity to avoid the mutilating,painful, expensive, and frequently unsuccessful surgical interventions of today that are applied to end-stage disease.For the present, clinicians should evaluate any woman with reproductive tract symptoms and leiomyomas carefully and with skepticism, ensuring that they have done all that is necessary to determine if the lesion or lesions are related to the problem. If leiomyomas are the suspected or known cause, clinicians must also be prepared to offer or otherwise provide access to the complete spectrum of care that the patient deserves, regardless of the limitations of the clinician’s training, experience,or institutional environment. Such an approach will limit the number of unnecessary and ineffective interventions and, it is hoped, minimize morbidity while optimizing quality of life for affected women.

Entities:  

Mesh:

Year:  2011        PMID: 22134018     DOI: 10.1016/j.ogc.2011.09.006

Source DB:  PubMed          Journal:  Obstet Gynecol Clin North Am        ISSN: 0889-8545            Impact factor:   2.844


  6 in total

1.  Injectable Clostridium histolyticum collagenase as a potential treatment for uterine fibroids.

Authors:  Lisa N Brunengraber; Friederike L Jayes; Phyllis C Leppert
Journal:  Reprod Sci       Date:  2014-10-20       Impact factor: 3.060

2.  Radiofrequency Volumetric Thermal Ablation of Fibroids and Laparoscopic Myomectomy: Long-Term Follow-up From a Randomized Trial.

Authors:  M Hahn; S Brucker; D Kraemer; M Wallwiener; F-A Taran; C W Wallwiener; B Krämer
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-05       Impact factor: 2.915

3.  Patients' age, myoma size, myoma location, and interval between myomectomy and pregnancy may influence the pregnancy rate and live birth rate after myomectomy.

Authors:  Ying Zhang; Ke Qin Hua
Journal:  J Laparoendosc Adv Surg Tech A       Date:  2013-12-24       Impact factor: 1.878

4.  Uterine Fibroid Embolisation - Potential Impact on Fertility and Pregnancy Outcome.

Authors:  M David; T Kröncke
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-03       Impact factor: 2.915

5.  Association of Single Nucleotide Polymorphism LEP-R c.668A>G (p.Gln223Arg, rs1137101) of leptin receptor gene with endometrial cancer.

Authors:  Jan Bieńkiewicz; Hanna Romanowicz; Miłosz Wilczyński; Grzegorz Jabłoński; Anna Stepowicz; Anna Obłękowska; Andrzej Malinowski; Beata Smolarz
Journal:  BMC Cancer       Date:  2021-08-16       Impact factor: 4.430

Review 6.  Biomarkers in abnormal uterine bleeding†.

Authors:  Rohan Chodankar; Hilary O D Critchley
Journal:  Biol Reprod       Date:  2019-12-24       Impact factor: 4.285

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.